News & Updates
Filter by Specialty:
CV benefits of dapagliflozin evident regardless of baseline kidney function
The cardiovascular (CV) benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is evident regardless of baseline kidney function, according to an analysis of the DELIVER* trial presented at Kidney Week 2022.
CV benefits of dapagliflozin evident regardless of baseline kidney function
11 Dec 2022
Edaravone confers neuroprotection in stroke patients
Edaravone appears to be safe and effective in the treatment of patients with ischaemic stroke, yielding improvements in activities of daily living and neurologic deficits in the short term, a study has found.
Edaravone confers neuroprotection in stroke patients
10 Dec 2022
Amivantamab/lazertinib combo shows promise in EGFR-mutated NSCLC
Among nonsmall cell lung cancer (NSCLC) patients with mutations spanning exons 18 to 21, combination treatment with amivantamab and lazertinib induces high rates of response, reports a study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).
Amivantamab/lazertinib combo shows promise in EGFR-mutated NSCLC
10 Dec 2022
Tralokinumab improves skin microbial dysbiosis in atopic dermatitis
In patients with atopic dermatitis (AD), treatment with the IL-13 cytokine-targeting tralokinumab appears to directly or indirectly improves skin microbial dysbiosis, reports a new trial.
